FDA Signs Onto EMA Analysis Of Incretin Mimetics; Labeling For Diabetes Drugs Is Adequate
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA finds no new concerns of pancreatic risks of GLP-1 based diabetes drugs, says worrisome study of tissue samples from organ donors has limitations.
You may also be interested in...
FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.